Who We Are
Xturnpoint focuses on advancing therapeutic innovations to earlier inflections in value by providing capital, partnerships, and industry expertise. Our agile operating model supports early-stage innovators as they progress towards their NXT critical milestone.
Our Model
Early- and seed-stage life sciences innovators have a core set of needs to advance their technology to IND and beyond. Addressing these requires strategic expertise, access to resources, and the flexibility to align with each innovator’s goals.
Xturnpoint brings a unique ability to meet the full spectrum of needs. Our differentiated approach supports early-stage drug development by defining a clear path forward and allowing potential partners to execute with confidence.
We support our partners by
increasing
operational
efficiency
offering validation of
clinical
and commercial opportunities
fostering long-term industry and academic partnerships
mitigating
risk
providing
access
to capital
contributing
to ecosystem
development
Partners
NYU Langone Health
Is one of the nation’s premier academic medical centers. Our trifold mission to care, teach, and discover is achieved daily through an integrated academic culture devoted to excellence in patient care, education, and research.
How can we partner with you?
Let's chatWhat We Do
We are dedicated to partnering with innovators to tackle the challenges of unmet needs by supporting you and your mission to advance life-changing therapeutics. Our goal is to add value at every stage, helping advance efforts through strategic expertise and capital towards the NXT development phase, bringing hope and relief to patients.
Vision
Where We Are Going
Opportunity analysis and hypothesis validation Xturnpoint identifies your key opportunities and tests assumptions to support informed decision-making.
Early-stage commercial positioning We combine clinical and regulatory insights to design pathways for market entry that minimize risks and maximize value.
Integrated partnership approach As an extension of your team, we develop long-term relationships with aligned incentives to help achieve your development goals.
Capital
Means to Execute
Strategic financial planning Xturnpoint offers tailored, flexible funding models to align investments with your specific requirements for optimal resource utilization.
Investment approach We provide modest upfront capital for opportunistic and collaborative venture creation.
Roadmap
How We Get There
Well-defined responsibilities Xturnpoint establishes clear team and partnership roles to foster collaboration and manage key operational tasks effectively.
Data-driven insights We leverage evidence-based insights to guide study design and regulatory engagements.
Aligned incentives We maintain precise coordination at key stages through structured project management.
Results
Ability to Execute
Access to cutting-edge discovery Xturnpoint connects you to advanced translational work and in-house expertise to drive innovation and decision-making.
Milestones and accelerated R&D timelines We help establish clear roadmaps to your NXT inflection point to streamline development and reduce your asset’s time to market.
Clinical-stage planning and execution We support your clinical development with an agile, experienced team to mitigate risks.
Research impact and adoption by healthcare providers We facilitate the transition from research to clinical practice and leverage a broad network of subject-matter experts and key opinion leaders towards impactful patient outcomes.
Enter your NXT phase of therapeutic development
Let's connectWhat’s
Beyond being your dedicated partner for your drug asset, Xturnpoint keeps you informed about our latest initiatives and developments. Find out what’s new and NXT in our innovations.
Connect
If you are an early- or seed-stage life sciences innovator, Xturnpoint invites you to share your vision, progress, and potential with us.
Together, we hope to form a meaningful collaboration if you are:
01
Developing early- or seed-stage assets positioned to solve unmet medical needs, aiming to generate proof-of-concept data
02
Managing ready-to-scale assets in early-phase testing in need of data-driven clinical and regulatory strategy with preclinical-stage expertise
03
Advancing pre-clinically validated assets seeking out-licensing or co-development opportunities
Xturnpoint Advisory Board
Tim Garnett, MD
As an innovative extension of Xentria, Xturnpoint’s advisory board is led by Dr. Tim Garnett. Dr. Garnett is a distinguished pharmaceutical-industry leader with more than 30 years of experience in clinical development, medical affairs, and regulatory operations.
As the former Chief Medical Officer at Eli Lilly, Dr. Garnett inspired and guided advancing treatments in women’s health, metabolic diseases, and CNS disorders. He has been influential in transforming drug safety and regulatory organizations and improving drug development and approval processes worldwide.
Powered by Xentria
Established in 2020, Xentria works across biopharmaceutics communities creating innovative and authentic collaborations and partnerships that advance challenging drug development. Xentria, derived from “centrality,” is dedicated to delivering customized approaches to ambitious drug innovation through meaningful patient engagement and effective partnerships. Headquartered in Chicago, Xentria is taking the lead to support surging life sciences initiatives for global audiences, while nurturing diversity, individualism, and sustainability.